Skip to main content

Advertisement

Log in

Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats’ disease

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

A Correction to this article was published on 14 May 2019

This article has been updated

Abstract

Purpose

To evaluate the efficacy of intravitreal bevacizumab injections combined with laser photocoagulation in the treatment of adult-onset Coats’ disease.

Methods

Thirteen eyes of 13 patients suffering from adult-onset Coats’ disease were retrospectively included and analyzed. All patients were treated at baseline using intravitreal bevacizumab injections combined with laser photocoagulation. Follow-up treatment was performed as necessary.

Results

The mean age of the subjects was 40.3 years, and the mean follow-up period was 24.8 months. The mean number of bevacizumab injections was 2.69, and the mean number of laser treatment sessions was 1.68. The mean baseline best-corrected visual acuity (BCVA) was 0.72 logarithm of the minimum angle of resolution (logMAR; 20/104 Snellen equivalent), while the mean BCVA at the final visit was 0.68 logMAR (20/95; P = 0.548). In three patients (23.0 %), BCVA had improved by more than 3 lines, and seven patients (54.0 %) showed stable BCVA (changes within 2 lines of visual acuity) after treatment. The mean central foveal thickness improved significantly, from 473 μm at baseline to 288 μm at the final visit (P = 0.023). Final BCVA was significantly correlated with a baseline BCVA (P < 0.001; ρ = 0.882). The final BCVA of patients who had subfoveal hard exudates at baseline was significantly worse than that of patients without such exudates (P = 0.005).

Conclusions

Intravitreal bevacizumab injection combined with laser photocoagulation may be an effective treatment option for adult-onset Coats’ disease. Both poor initial BCVA and the occurrence of subfoveal hard exudates at baseline were associated with poor prognosis and poor therapeutic response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Change history

  • 14 May 2019

    The IRB number of the published article was A-2015-016 (page 1512, 1st paragraph of the method section).

  • 14 May 2019

    The IRB number of the published article was A-2015-016 (page 1512, 1st paragraph of the method section).

References

  1. Shields JA, Shields CL, Honavar SG, Demirci H (2001) Clinical variations and complications of coats diseased in 150 cases: the 200 Sanford Gifford memorial lecture. Am J Ophthalmol 131:561–571

    Article  CAS  PubMed  Google Scholar 

  2. Smithen LM, Brown GC, Brucker AJ, Yannuzzi LA, Klais CM, Spaide RF (2005) Coats’ disease diagnosed in adulthood. Ophthalmology 112:1072–1078

    Article  PubMed  Google Scholar 

  3. Lai CH, Kuo HK, Wu PC, Kuo ML, Chen YJ (2007) Manifestation of coats’ disease by age in Taiwan. Clin Exp Ophthalmol 35:361–365

    Article  Google Scholar 

  4. Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG (2014) Current management of coats disease. Surv Ophthalmol 59:30–46

    Article  PubMed  Google Scholar 

  5. Zheng XX, Jiang YR (2014) The effect of intravitreal bevacizumab injection as the initial treatment for coats’ disease. Graefes Arch Clin Exp Ophthalmol 252:35–42

    Article  CAS  PubMed  Google Scholar 

  6. Lin CJ, Hwang JF, Chen YT, Chen SN (2010) The effect of intravitreal bevacizumab in the treatment of coats disease in children. Retina 30:617–622

    Article  PubMed  Google Scholar 

  7. Ghorbanian S, Jaulim A, Chartziralli IP (2012) Diagnosis and treatment of coats’ disease: a review of the literature. Ophthalmologica 227:175–182

    Article  CAS  PubMed  Google Scholar 

  8. Galliard MC, Mataftsi A, Balmer A, Houghton S, Munier FL (2014) Ranibizumab in the management of advanced coats disease stages 3B and 4. Retina 34:2275–2281

    Article  Google Scholar 

  9. Wang KY, Cheng CK (2011) A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset coats’ disease. J Ocul Pharmacol Ther 27:525–530

    Article  PubMed  Google Scholar 

  10. Böhm MR, Uhlig CE (2011) Use of intravitreal triamcinolone and bevacizumab in coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol 249:1099–1101

    Article  PubMed  Google Scholar 

  11. Kim J, Park KH, Woo SJ (2010) Combined photodynamic therapy and intravitreal bevacizumab injection for the treatment of adult coats’ disease: a case report. Korean J Ophthalmol 24:374–376

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zhao Q, Peng XY, Chen FH et al (2014) Vascular endothelial growth factor in coats’ disease. Acta Ophthlamol 92:225–228

    Article  Google Scholar 

  13. Kase S, Rao NA, Yoshikawa H et al (2013) Expression of vascular endothelial growth factor in eyes with coats’ disease. Invest Ophthalmol Vis Sci 54:57–62

    Article  CAS  PubMed  Google Scholar 

  14. He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J (2010) Elevated vascular endothelial growth factor level in coat’s disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol 248:1519–1521

    Article  CAS  PubMed  Google Scholar 

  15. Sun Y, Jain A, Moshfeghi DM (2007) Elevated vascular endothelial growth factor levels in coats’ disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol 245:1387–1388

    Article  CAS  PubMed  Google Scholar 

  16. Domalpally A, Ip MS, Ehrlich JS (2015) Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology 122:779–786

    Article  PubMed  Google Scholar 

  17. Ramasubramanian A, Shields CL (2012) Bevacizumab for coats’ diease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 96:356–359

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Han Joo Cho.

Ethics declarations

Funding

No funding was received for this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, S., Cho, H.J., Lee, D.W. et al. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats’ disease. Graefes Arch Clin Exp Ophthalmol 254, 1511–1517 (2016). https://doi.org/10.1007/s00417-015-3233-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-015-3233-6

Keywords

Navigation